Press Releases 2014
New data for the Lotus™ Valve System announced at PCR London Valves - Sep 29, 2014
30-Day outcomes for the 250 patients enrolled in REPRISE II Extended Cohort trial were presented by Prof Ian Meredith at PCR London Valves on September 29th.
Boston Scientific Enrolls First Patients In U.S. Trial Of The Lotus™ Valve System - Sep 23, 2014
Data From REPRISE III Clinical Trial Designed to Support U.S. Regulatory Approval
Boston Scientific at EuroPCR 2014 - Jun 13, 2014
A short video summary of EuroPCR2014, including the latest clinical data from the EVOLVE and REPRISE II studies, presented by Dr Keith G. Oldroyd and Dr Daniel Blackman.
Boston Scientific Initiates the RESPOND Post Market Registry Evaluating Clinical Outcomes in Patients Implanted With Lotus™ Valve System - Jun 04, 2014
Boston Scientific Corporation (NYSE: BSX) has initiated the RESPOND Post Market Registry to assess real world performance of the Lotus™ Valve System. The RESPOND...
Boston Scientific Lotus™ Valve System demonstrates strong performance and safety profile at six months - May 21, 2014
Only 1.1 Percent of Patients Experienced Moderate Paravalvular Aortic Regurgitation; No Severe Cases Occurred
Boston Scientific Lotus™ Valve System demonstrates strong performance - Apr 01, 2014
These and Other Studies Reinforce Global Commitment to the Development of Innovative Therapies to Improve Care for Patients with Cardiovascular Disease. Reinforcing its position as a global...
Media Contacts
Rosie Ireland
Corporate Communications
+44 7585403359
rosie.ireland@bsci.com